Why Goldman Sachs Raised Its Price Target On This Biotech Stock By Nearly 5X
- ByBenzinga-
The initial phase II data in patients with hypothalamic obesity (HO) has transformed the opportunity for Rhythm Pharmaceuticals Inc’s (NASDAQ: RYTM) Imcivree, according to...